Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus (NASDAQ: TARS) announced management will participate in three investor conferences in May 2026: Bank of America Health Care Conference on May 12 (3:40 p.m. PT / 6:40 p.m. ET), H.C. Wainwright BioConnect on May 19 (8:00 a.m. PT / 11:00 a.m. ET), and Stifel Virtual Ophthalmology Forum on May 26 (12:30 p.m. PT / 3:30 p.m. ET).
Live webcasts and additional details are available on the company's events page. Replays will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported Q1 2026 XDEMVY net product sales of $145.4M, up >85% year-over-year, and reaffirmed full-year 2026 XDEMVY guidance of $670–700M with peak sales potential exceeding $2 billion. Cash and marketable securities totaled $388.7M. The company initiated a Phase 2 trial for TP-05 and expects multiple topline readouts in H1 2027.
Management will host a conference call on May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
Tarsus Pharmaceuticals (NASDAQ: TARS) will report first quarter 2026 financial results on Wednesday, May 6, 2026 with a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. A recorded version will be posted to the company's website shortly after the call and archived for approximately 90 days.
Tarsus (NASDAQ: TARS) dosed the first participant in Calliope, a randomized, double-blind Phase 2 trial of TP-05 (lotilaner) to evaluate safety, tolerability and pharmacokinetics for potential prevention of Lyme disease by killing infected ticks before transmission.
Calliope will enroll ~700 healthy adults across U.S. endemic regions, aims to complete enrollment during the 2026 tick season, and expects topline results in H1 2027. Prior Phase 2a Carpo showed >90% tick kill within 24 hours and statistically significant benefit versus placebo (p<0.001); preclinical mouse studies showed 90% efficacy versus 0% in controls.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced a $15 million milestone payment after Grand Pharmaceutical Group obtained NMPA approval in China for TP-03 (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis. The approval covers the Greater China region and triggers agreed patent-related and regulatory milestones.
Under the partnership, Tarsus may receive additional payments for regulatory milestones, China sales thresholds, and tiered royalties tied to TP-03 commercial performance in the region.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced management will participate in upcoming investor conferences in early March 2026. Presentations are scheduled at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:30 a.m. PT / 2:30 p.m. ET and at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 9:30 a.m. PT / 12:30 p.m. ET.
Live webcasts and event details are available on the company website. Replays will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported full-year 2025 net product sales for XDEMVY of $451.4 million (up >150% YoY) and Q4 sales of $151.7 million. The company delivered ~400,000 bottles in 2025, maintains >90% payer coverage, and ended Year‑end cash of $417.3 million. Pipeline progress includes a Phase 2 start for TP-04 and a planned TP-05 Phase 2 in Q2 2026.
Management expects XDEMVY peak sales potential >$2 billion and noted ongoing regulatory paths in Europe, Japan, and Greater China.
Tarsus Pharmaceuticals (NASDAQ: TARS) appointed David E. I. Pyott, former Allergan CEO, to its Board of Directors on February 18, 2026.
Mr. Pyott brings 17 years of leadership at Allergan, growing sales from about $1 billion to more than $7 billion, and experience across R&D, product development and commercial execution to support XDEMVY and the pipeline.
Tarsus (NASDAQ: TARS) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026. A live webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET, with a recorded replay available on the company website and archived for about 90 days.
The company will provide a corporate update during the call; investors can access the live webcast via the company’s investor site.
Tarsus (NASDAQ:TARS) said management will participate in a fireside chat at BTIG 5th Annual Ophthalmology Day on Monday, December 1, 2025 at 10:45 a.m. PT / 1:45 p.m. ET.
A live webcast will be available on the events section of the Tarsus website, and a replay will be posted within 48 hours and archived for a limited time.